载药微球经导管动脉栓塞化疗治疗肝癌的有效性及安全性  

Clinical study on the efficacy and safety of DEB-TACE in the treatment of liver cancer patients

作　　者：郝爱芹 张栋华[1] 李文[1] 王宪红[1] HAO Aiqin;ZHANG Donghua;LI Wen;WANG Xianhong(Department of Liver Diseases,the Fifth People’s Hospital of Anyang,Anyang 455000,He’nan,China)

机构地区：[1]安阳市第五人民医院肝病科,河南安阳455000

出　　处：《癌症进展》2020年第16期1700-1703,共4页Oncology Progress

摘　　要：目的探讨载药微球经导管动脉栓塞化疗(TACE)治疗原发性肝癌的效果。方法依据治疗方式将98例原发性肝癌患者分为研究组和对照组,每组49例,研究组患者接受Calli Spheres载药微球TACE治疗,对照组患者接受传统TACE治疗。比较两组患者化疗结束后的疗效和不良反应发生情况;治疗前后,比较两组患者血清血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bEGF)水平和肝功能指标[包括总胆红素(TB)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、转肽酶(γ-GT)、白蛋白(ALB)、碱性磷酸酶(ALP)]。结果研究组患者的客观缓解率为89.80%,高于对照组患者的71.43%,差异有统计学意义(P﹤0.05)。治疗后,研究组患者血清VEGF、bEGF水平均低于对照组患者,两组患者血清TB、ALT、AST、ALP水平均高于本组治疗前,ALB水平均低于本组治疗前,差异均有统计学意义(P﹤0.05)。两组患者栓塞后综合征、腹腔积液、恶心呕吐、乏力的发生率比较,差异均无统计学意义(P﹥0.05)。结论载药微球TACE治疗原发性肝癌的效果优于传统的TACE方式,可明显改善患者的血清VEGF、bEGF水平。Objective To investigate the effect of drug-eluting beads transarterial chemoembolization(DEB-TACE)in the treatment of primary liver cancer.Method According to the treatment method,98 patients with primary liver cancer were divided into study group or control group,with 49 cases in each.Patients in the study group received DEBTACE treatment with Calli Spheres,and patients in the control group were given traditional TACE.The efficacy and adverse reactions of the two groups of patients after chemotherapy were compared;before and after treatment,the serum vascular endothelial growth factor(VEGF),basic epidermal growth factor(bEGF)levels and liver function markers[including total bilirubin(TB),alanine aminotransferase(ALT),aspartate aminotransferase(AST),gamma glutamyl transferase(γ-GT),albumin(ALB),alkaline phosphatase(ALP)]were compared between the two groups.Result The objective response rate in study group was 89.80%,which was higher than that of the control group at 71.43%,and the difference was statistically significant(P<0.05).After treatment,the levels of serum VEGF,bEGF in study group patients were lower compared to those in control group,while the serum TB,ALT,AST,and ALP levels were increased,while ALB was decreased in the two groups after treatment,with statistically significant difference observed(P<0.05).The incidence of post-embolization,ascites,nausea and vomiting,and fatigue in the two groups were similar(P>0.05).Conclusion DEBTACE is better than traditional TACE in the treatment of primary liver cancer,and may evidently improve the serum levels of VEGF and bEGF.

关 键 词：载药微球 经导管动脉栓塞化疗 原发性肝癌 血管内皮生长因子 碱性成纤维细胞生长因子 

分 类 号：R735.7[医药卫生—肿瘤]